All I am seeing is probably the same as you; still in Phase 2b trials for moderate to severe Tourette’s. The bigger worry I have is that it will be a brand name only for a while… which will require a prior authorization from the doc with the insurance company… and the use will be off-label and the insurance company will deny it. That being said, once it comes to market, I’m sure they will try to expand the indication to stuttering